Vistagen Wins FDA Backing for LSAS Endpoint in Future Phase 3 of Fasedienol
VTGN is trading near its 52-week low of $0.164 (5.0% above the low) on light trading volume (0.1× avg).
Summary
Vistagen said its Type C meeting with FDA produced constructive feedback on using LSAS as the primary endpoint in a future Phase 3 study of fasedienol for social anxiety disorder, and it will submit a revised protocol. The path is clearer, but funding a new Phase 3 remains the open question given going-concern doubt.
Key Events · Product Development and Regulatory · VTGN
-
FDA Backs LSAS Endpoint Concept
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study of fasedienol in adults with social anxiety disorder.
-
Interim Assessments Added to Design
FDA recommended interim assessments to test whether acute effects lead to longer-term overall functional improvement; Vistagen will add eDiaries and qualitative patient surveys and submit a revised protocol.
-
Broader SAD Population Targeted
Based on the feedback, Vistagen will focus future development on the general SAD population and pursue overall, not just acute, treatment of SAD.
-
Financing Still the Binding Constraint
The company previously reported a $13.0M quarterly net loss, going-concern doubt and a Nasdaq compliance extension to February 2027; no funding for a new Phase 3 is disclosed in this filing.
Analysis · VTGN · Life Sciences
This is the first substantive regulatory read on fasedienol since the PALISADE-4 miss in August, and it keeps a registrational path alive: FDA accepted the LSAS-based design concept and suggested interim assessments to show acute effects translate into longer-term functional benefit. The company now plans to broaden the target to the general SAD population and overall treatment rather than just acute use, which widens the potential label. Nothing here is an approval or a guarantee — FDA can still demand more studies — and the bigger constraint is money: with a $13.0M quarterly loss, going-concern doubt and a Nasdaq compliance deadline in February 2027, a new Phase 3 will require financing the company has not yet secured.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTGN was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.16 to $5.14. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.